Fingolimod is a first-in-class sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of patients with relapsing multiple sclerosis (MS). The clinical effect has been attributed mainly to its capacity to sequester circulating lymphocytes into secondary lymphoid tissues. 1 The CD4+ T cell population, in particular the CCR7+ subpopulations, are preferentially retained in the lymph nodes which results in profound changes in the composition of T cells in peripheral blood. This includes an inversion of the CD4/CD8 T cell ratio. 2,3 These changes may not only affect the total lymphocyte count (TLC) and the lymphocyte phenotype as assessed by surface and cytokine expression but could also alter the T cell receptor (TCR) repertoire and the gene expression signature of circulating immune cells. 4, 5 In addition, fingolimod may also affect the interaction of cells of the innate immune system with T cells by diminishing the pro-inflammatory capabilities of antigen-presenting cells 6 and induce inter-individually distinct changes to Th17 and regulatory T cell subpopulations. 7 While alterations in the cellular composition of immune cells before and during continued therapy with fingolimod have been assessed in several studies, the extent, timing, and pattern of reconstitution of the immune repertoire after treatment cessation have not yet been investigated systematically. However, such studies may be of clinical relevance as changes that persist after treatment stops may put patients at higher risk of unwanted therapeutic effects. These include infectious or immune-mediated complications, for example, during a subsequent alternative disease-modifying therapy for MS.
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In this issue of the journal, Ghadiri and colleagues studied the immune repertoire of peripheral blood lymphocytes following cessation of fingolimod treatment. A total of 18 patients were recruited into the study. TLC and CD4+/CD8+ counts were obtained from routine clinical testing. T cell subsets were analyzed by fluorescence-activated cell scanning (FACS) analysis on cryopreserved peripheral blood mononuclear cells (PBMCs) using the T cell activation markers CCR7 and CD45RA, as well as antibodies to label regulatory T cells and recent thymic emigrants. As expected, fingolimod reduced the TLC to around 22% of baseline and inverted the CD4/CD8 ratio. As previously published, CD4+CCR7+ naive and central memory T cells were predominantly affected. A novel finding was the early reconstitution at 2 weeks of fingolimod cessation which was partial and inter-individually different: TLC only increased to 31% of baseline, mainly driven by partial recovery of absolute CD4 T cell numbers. It took until 2-3 months that the CD4/CD8 ratio returned to values higher than 75% of baseline and until 8-9 months that at least 90% of the individual pre-treatment values of TLCs were reached. In particular, the naive T cell population recovered slowly, reaching only 58% or 32% of pre-treatment levels in the CD4 or CD8 population, respectively.
Although this study has several limitations, foremost being the limited number of the patients included and the use of cryopreserved PBMCs for the assessment of lymphocyte subpopulations, it is reassuring to see that TLC generally do recover. However, this recovery may take 8-9 months and seems to depend largely on the CD4+ T cells returning. What is the clinical meaning of these findings? The article by Ghadiri and colleagues suggests that the only partial reversibility of the profound changes to TLC levels and the cellular composition of the peripheral blood seen in MS patients treated with fingolimod may impart or contribute to risks of consecutive immune therapy. Certainly, smaller-scope studies such as the study presented are underpowered to directly address such a link. Indeed, blood biomarkers that could reliably predict therapeutic responses in MS are lacking, and those that have been introduced, for example, for stratification of patients at higher or lower risk of developing adverse events such as progressive multifocal leukoencephalopathy (PML) have been validated for therapy with natalizumab only in larger cohorts (anti-JC virus antibodies), or have been based on single case observations, such as the assumed higher risk of PML in patients with low TLCs during exposure to fumarates. 8 Interestingly, to the best of our knowledge, none of the studies published to date were able to directly relate TLCs, cellular surface expression, or alternative blood markers to efficacy or adverse events during therapy with fingolimod. Is this simply explained by a lack of power? Could it not be valid to transfer knowledge from other fields, such as the HIV field, or from experience in the use of other MS therapeutics to fingolimod? Do the low TLCs-as suggested for treatment with fumarates-and the low CD4+ T cell counts-as observed in HIV-put the patients at a higher risk of developing opportunistic infections such as PML? Although such analogy appears to have face value, it might miss out the different mode of action by which several drugs interfere with the control of diverse infectious pathogens. Looking at TLCs, these might be elevated during treatment with natalizumab, and still these patients are at the highest risk of developing PML compared with all other therapies registered for MS. In one of the cases that developed PML during therapy with fumaric acid, only moderate lymphopenia occurred and CD4+ T cells were relatively spared compared with CD8+ T cells. 9 This differs from what is usually seen in AIDS patients who develop opportunistic infections. It is important to realize that our understanding of the changes to the immune system during interference with the S1P receptor system is just evolving. It is established that the S1P receptor signaling system is not only involved in lymphocyte egress but also regulates various complex processes including vascular development, endothelial integrity, and control of cardiac rhythm. 10 We know that the therapeutic effects are generally reversible. Although the study discussed here suggests that this reversibility may occur rather late, it is unclear how this translates to the ability of the immune system to deal with the exposure to a neo-antigen, or re-exposure to a known, or a known but partly altered pathogen, such as a PML-type variant of JC virus.
One should note that the observations reported in this and also other biomarker studies thus far do not allow direct clinical conclusions, for example, with regard to an optimal washout period for a drug such as fingolimod, or a marker that predicts treatment response or adverse events. Besides assessing the surface expression phenotype of the T cell subpopulations, other strategies might add novel insights, for example, examination of the diversity 11 and the specificity of the TCR repertoire of the reconstituting peripheral T cell pool. 12 In addition, it will be of interest to study immune cell reconstitution following exposure to selective S1P receptor modulators with shorter half lives currently under development. 13, 14 Large postmarketing observational programs will be needed to capture superiority of these novel compounds with regard to long-term efficacy and rare side effects and for the development of predictive biomarkers that can aid in making individualized MS treatment decisions. 
